Drug Profile


Alternative Names: CP-99,219; Trovafloxacin mesylate; Trovan; Turvel

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antibacterials; Fluoroquinolones; Naphthyridines
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Bacterial infections; Genital tract infections
  • Market Withdrawal Respiratory tract infections
  • Discontinued Toxoplasmosis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 20 Mar 2001 The European Commission has formally withdrawn the marketing authorisations in the European Union for trovafloxacin and alatrofloxacin
  • 20 Mar 2001 Withdrawn for Bacterial infections in European Union (PO), including Austria, Denmark, Finland, The Netherlands, Portugal and Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top